Display options
Cite
McDew-White M, Lee E, Alvarez X, et al. Cannabinoid control of gingival immune activation in chronically SIV-infected rhesus macaques involves modulation of the indoleamine-2,3-dioxygenase-1 pathway and salivary microbiome. EBioMedicine. 2021;75:103769doi: 10.1016/j.ebiom.2021.103769.
McDew-White, M., Lee, E., Alvarez, X., Sestak, K., Ling, B. J., Byrareddy, S. N., Okeoma, C. M., & Mohan, M. (2021). Cannabinoid control of gingival immune activation in chronically SIV-infected rhesus macaques involves modulation of the indoleamine-2,3-dioxygenase-1 pathway and salivary microbiome. EBioMedicine, 75103769. https://doi.org/10.1016/j.ebiom.2021.103769
McDew-White, Marina, et al. "Cannabinoid control of gingival immune activation in chronically SIV-infected rhesus macaques involves modulation of the indoleamine-2,3-dioxygenase-1 pathway and salivary microbiome." EBioMedicine vol. 75 (2021): 103769. doi: https://doi.org/10.1016/j.ebiom.2021.103769
McDew-White M, Lee E, Alvarez X, Sestak K, Ling BJ, Byrareddy SN, Okeoma CM, Mohan M. Cannabinoid control of gingival immune activation in chronically SIV-infected rhesus macaques involves modulation of the indoleamine-2,3-dioxygenase-1 pathway and salivary microbiome. EBioMedicine. 2021 Dec 23;75:103769. doi: 10.1016/j.ebiom.2021.103769. Epub 2021 Dec 23. PMID: 34954656.
Copy Download .nbib Format: NLM
Share it on

EBioMedicine. 2021 Dec 23;75:103769. doi: 10.1016/j.ebiom.2021.103769. Epub 2021 Dec 23.

Cannabinoid control of gingival immune activation in chronically SIV-infected rhesus macaques involves modulation of the indoleamine-2,3-dioxygenase-1 pathway and salivary microbiome.

EBioMedicine

Marina McDew-White, Eunhee Lee, Xavier Alvarez, Karol Sestak, Binhua J Ling, Siddappa N Byrareddy, Chioma M Okeoma, Mahesh Mohan

Affiliations

  1. Texas Biomedical Research Institute, Southwest National Primate Research Center, 8715 West Military Road, San Antonio, TX 78227, United States.
  2. PreCliniTria, LLC., Mandeville, LA 70471, United States; Tulane National Primate Research Center, Covington LA 70433, United States.
  3. Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, United States.
  4. Department of Pharmacology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794-8651, United States.
  5. Texas Biomedical Research Institute, Southwest National Primate Research Center, 8715 West Military Road, San Antonio, TX 78227, United States. Electronic address: [email protected].

PMID: 34954656 DOI: 10.1016/j.ebiom.2021.103769

Abstract

BACKGROUND: HIV/SIV-associated periodontal disease (gingivitis/periodontitis) (PD) represents a major comorbidity affecting people living with HIV (PLWH) on combination anti-retroviral therapy (cART). PD is characterized by chronic inflammation and dysbiosis. Nevertheless, the molecular mechanisms and use of feasible therapeutic strategies to reduce/reverse inflammation and dysbiosis remain understudied and unaddressed.

METHODS: Employing a systems biology approach, we report molecular, metabolome and microbiome changes underlying PD and its modulation by phytocannabinoids [delta-9-tetrahydrocannabinol (Δ

FINDINGS: VEH- untreated/SIV but not THC/SIV RMs showed significant enrichment of genes linked to anti-viral defense, interferon-β, NFκB, RIG-1, and JAK-STAT signaling. We focused on the anti-microbial DUOX1 and immune activation marker IDO1 that were reciprocally regulated in the gingiva of VEH-untreated/SIV RMs. Both proteins localized to the gingival epithelium and CD163

INTERPRETATION: The data provides deeper insights into the molecular mechanisms underlying HIV/SIV-induced PD and more importantly, the anti-inflammatory and anti-dysbiotic properties of THC in the oral cavity. Overall, these translational findings suggest that phytocannabinoids may help reduce gingival/systemic inflammation, salivary dysbiosis and potentially metabolic disease/syndrome in PLWH on cART and those with no access to cART or do not suppress the virus under cART.

FUNDING: Research reported in this publication was supported by the National Institutes of Health Award Numbers R01DA052845 (MM and SNB), R01DA050169 (MM and CO), R01DA042524 and R56DE026930 (MM), and P51OD011104 and P51OD011133. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

Keywords: Bifidobacteria; DUOX1; Gingival inflammation; IDO1; Lactobacilli; Prevotella; Rhesus macaque; SIV; THC; miR-125a-5p

Conflict of interest statement

Declaration of interests All authors declare no conflict of interests.

Publication Types